EP Biocomposites Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1003694,
    "name": "EP Biocomposites",
    "stock_name": "EP Biocomposites",
    "full_name": "EP Biocomposites Ltd",
    "name_url": "stocks-analysis/ep-biocomposites",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "90.00",
    "chg": -4,
    "chgp": "-4.26%",
    "dir": -1,
    "prev_price": "94.00",
    "mcapval": "16.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 543595,
    "symbol": "",
    "ind_name": "Other Utilities",
    "ind_code": 67,
    "indexname": "",
    "isin": "INE0D2I01014",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": 2500,
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ep-biocomposites-1003694-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is EP Biocomposites overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ep-biocomposites-overvalued-or-undervalued-3716787",
        "imagepath": "",
        "date": "2025-11-20 08:07:30",
        "description": "As of 19 November 2025, EP Biocomposites has moved from a fair valuation to an expensive rating. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 15.35, an EV to EBIT of 11.15, and a ROCE of 12.38%. \n\nIn comparison to its peers, EP Biocomposites' PE ratio is significantly lower than that of Altius Telecom, which has a PE of 51.84, indicating that EP Biocomposites is not positioned favorably within its industry. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -45.03% compared to the Sensex's 9.02%, further reinforcing the notion that the stock is overvalued...."
      },
      {
        "title": "Is EP Biocomposites overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ep-biocomposites-overvalued-or-undervalued-3709968",
        "imagepath": "",
        "date": "2025-11-18 08:25:50",
        "description": "As of 17 November 2025, the valuation grade for EP Biocomposites has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 15.35, an EV to EBIT of 11.15, and an ROCE of 12.38%. \n\nIn comparison to peers, EP Biocomposites has a similar valuation to Sagility, which is also rated fair with a PE of 29.82, but significantly lower than Altius Telecom, which is rated very attractive with a PE of 51.5. Notably, EP Biocomposites has seen a substantial decline in stock performance, with a year-to-date return of -45.03%, contrasting sharply with the Sensex's gain of 8.72% during the same period...."
      },
      {
        "title": "Is EP Biocomposites overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ep-biocomposites-overvalued-or-undervalued-3687794",
        "imagepath": "",
        "date": "2025-11-11 08:14:03",
        "description": "As of 10 November 2025, the valuation grade for EP Biocomposites has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE Ratio of 17.14, an EV to EBITDA of 11.50, and a Price to Book Value of 1.65. In comparison, Altius Telecom, which is rated very attractive, has a significantly higher PE Ratio of 56.22, while Sagility, rated fair, has a PE Ratio of 29.75.\n\nThe recent performance of EP Biocomposites has been notably poor, with a year-to-date stock return of -38.6%, contrasting sharply with a Sensex return of 6.91% over the same period. This underperformance further supports the conclusion that the company is overvalued relative to its peers and the broader market...."
      },
      {
        "title": "How has been the historical performance of EP Biocomposites?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-ep-biocomposites-3668290",
        "imagepath": "",
        "date": "2025-11-03 22:58:14",
        "description": "Answer:\nThe historical performance of EP Biocomposites shows a progressive increase in net sales and profitability over the years, with notable fluctuations in certain metrics.\n\nBreakdown:\nEP Biocomposites has demonstrated a steady growth in net sales, rising from 2.95 Cr in Mar'21 to 12.01 Cr in Mar'25. The total operating income followed a similar trend, increasing from 2.95 Cr in Mar'21 to 12.01 Cr in Mar'25. However, the raw material costs also escalated, reaching 7.98 Cr in Mar'25 from 1.79 Cr in Mar'21. Operating profit, excluding other income, improved from 0.46 Cr in Mar'21 to 1.78 Cr in Mar'25, while the overall operating profit, including other income, increased from 0.46 Cr to 1.89 Cr in the same period. Profit before tax peaked at 1.42 Cr in Mar'25, although it slightly declined from 1.57 Cr in Mar'24. Profit after tax also saw growth, reaching 1.03 Cr in Mar'25 compared to 0.36 Cr in Mar'21. Th..."
      },
      {
        "title": "When is the next results date for EP Biocomposites?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-ep-biocomposites-3663065",
        "imagepath": "",
        "date": "2025-10-31 23:17:16",
        "description": "The next results date for EP Biocomposites is scheduled for November 3, 2025...."
      },
      {
        "title": "Why is EP Biocomposites falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-ep-biocomposites-fallingrising-3653233",
        "imagepath": "",
        "date": "2025-10-28 23:03:20",
        "description": "As of 27-Oct, EP Biocomposites Ltd is experiencing a decline in its stock price, currently at 123.00, which represents a decrease of 13.0 points or 9.56%. The stock has underperformed its sector today by 10.17%, opening with a significant loss of 13.16% and touching an intraday low of Rs 118.1. Over the past week, the stock has decreased by 2.38%, and year-to-date, it has fallen by 28.07%. Additionally, there has been erratic trading, with the stock not trading on 2 out of the last 20 days, and a notable drop in investor participation, as evidenced by a 37.5% decrease in delivery volume compared to the 5-day average. Unfortunately, there is no information available regarding positive or negative factors impacting the stock.\n\nBroader market context shows that while EP Biocomposites has struggled, the Sensex has gained 0.49% over the past week and 8.50% year-to-date. This stark contrast highlights the stock's..."
      },
      {
        "title": "Why is EP Biocomposites falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-ep-biocomposites-fallingrising-3645193",
        "imagepath": "",
        "date": "2025-10-24 23:57:38",
        "description": "As of 24-Oct, EP Biocomposites Ltd's stock price is rising, currently at 136.00, reflecting an increase of 11.0 points or 8.8%. The stock opened with a significant gain of 8.8% today and has maintained this price level throughout the trading session. It has outperformed its sector by 9.91%, and there has been a notable increase in investor participation, with delivery volume rising by 11.11% compared to the 5-day average. Despite a year-to-date decline of 20.47% and a 1-year drop of 22.73%, the recent performance indicates a positive shift, particularly in the short term.\n\nIn the broader market context, EP Biocomposites' 1-week return of 7.94% significantly outpaces the Sensex's modest gain of 0.31%, indicating a strong short-term performance relative to the benchmark. However, over the longer term, the stock has underperformed, with a 3-year decline of 53.10% compared to the Sensex's rise of 40.75%. This c..."
      },
      {
        "title": "Is EP Biocomposites overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ep-biocomposites-overvalued-or-undervalued-3608853",
        "imagepath": "",
        "date": "2025-10-10 08:06:13",
        "description": "As of 9 October 2025, the valuation grade for EP Biocomposites has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE Ratio of 20.73, an EV to EBITDA of 12.76, and a Price to Book Value of 2.02, which suggest that the stock is trading at a premium compared to its earnings and book value.\n\nIn comparison to its peers, EP Biocomposites has a lower PE ratio than Altius Telecom, which stands at 54.74, but is higher than Embassy Off.REIT at 25.21. The PEG ratio for EP Biocomposites is notably 0.00, indicating no growth expectations factored into its valuation, which is concerning. Additionally, the company's stock has underperformed relative to the Sensex, with a year-to-date return of -25.73% compared to the Sensex's 5.16%, reinforcing the notion that the stock is overvalued in the current market e..."
      },
      {
        "title": "Why is EP Biocomposites falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-ep-biocomposites-fallingrising-3605351",
        "imagepath": "",
        "date": "2025-10-09 00:11:06",
        "description": "As of 08-Oct, EP Biocomposites Ltd is currently priced at 120.00, with no change in price (0.00%). The stock has shown a significant decline over various periods, with a 6.21% drop in the past week and a 29.82% decrease year-to-date. Today's trading performance is inline with the sector, but the stock has exhibited erratic trading patterns, not trading on 3 out of the last 20 days. Additionally, it is trading below all key moving averages, indicating a bearish trend. However, there has been a notable increase in investor participation, with delivery volume rising by 650% against the 5-day average, suggesting some interest despite the overall downward trajectory.\n\nBroader Market Context: In comparison to the benchmark, the Sensex has performed positively, gaining 0.98% over the past week and 4.65% year-to-date, while EP Biocomposites has faced substantial losses. This stark contrast highlights the stock's un..."
      }
    ],
    "total": 62,
    "sid": "1003694",
    "stock_news_url": "https://www.marketsmojo.com/news/ep-biocomposites-1003694"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting- Financial Results For The Half Year Ended September 30 2025",
      "datetime": "03-Nov-2025",
      "details": "Outcome of the Board Meeting- Financial results for the half year ended September 30 2025",
      "source": "BSE"
    },
    {
      "caption": "Financial Results For The Half Year Ended September 30 2025",
      "datetime": "03-Nov-2025",
      "details": "Financial results for the half year ended September 30 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Consideration Of The Financial Results For The Half Year Ended September 30 2025",
      "datetime": "30-Oct-2025",
      "details": "EP Biocomposites Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2025 inter alia to consider and approve the financial results for the half year ended September 30 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is EP Biocomposites overvalued or undervalued?

2025-11-20 08:07:30

As of 19 November 2025, EP Biocomposites has moved from a fair valuation to an expensive rating. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 15.35, an EV to EBIT of 11.15, and a ROCE of 12.38%. In comparison to its peers, EP Biocomposites' PE ratio is significantly lower than that of Altius Telecom, which has a PE of 51.84, indicating that EP Biocomposites is not positioned favorably within its industry. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -45.03% compared to the Sensex's 9.02%, further reinforcing the notion that the stock is overvalued....

Is EP Biocomposites overvalued or undervalued?

2025-11-18 08:25:50

As of 17 November 2025, the valuation grade for EP Biocomposites has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 15.35, an EV to EBIT of 11.15, and an ROCE of 12.38%. In comparison to peers, EP Biocomposites has a similar valuation to Sagility, which is also rated fair with a PE of 29.82, but significantly lower than Altius Telecom, which is rated very attractive with a PE of 51.5. Notably, EP Biocomposites has seen a substantial decline in stock performance, with a year-to-date return of -45.03%, contrasting sharply with the Sensex's gain of 8.72% during the same period....

Is EP Biocomposites overvalued or undervalued?

2025-11-11 08:14:03

As of 10 November 2025, the valuation grade for EP Biocomposites has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE Ratio of 17.14, an EV to EBITDA of 11.50, and a Price to Book Value of 1.65. In comparison, Altius Telecom, which is rated very attractive, has a significantly higher PE Ratio of 56.22, while Sagility, rated fair, has a PE Ratio of 29.75. The recent performance of EP Biocomposites has been notably poor, with a year-to-date stock return of -38.6%, contrasting sharply with a Sensex return of 6.91% over the same period. This underperformance further supports the conclusion that the company is overvalued relative to its peers and the broader market....

How has been the historical performance of EP Biocomposites?

2025-11-03 22:58:14

Answer: The historical performance of EP Biocomposites shows a progressive increase in net sales and profitability over the years, with notable fluctuations in certain metrics. Breakdown: EP Biocomposites has demonstrated a steady growth in net sales, rising from 2.95 Cr in Mar'21 to 12.01 Cr in Mar'25. The total operating income followed a similar trend, increasing from 2.95 Cr in Mar'21 to 12.01 Cr in Mar'25. However, the raw material costs also escalated, reaching 7.98 Cr in Mar'25 from 1.79 Cr in Mar'21. Operating profit, excluding other income, improved from 0.46 Cr in Mar'21 to 1.78 Cr in Mar'25, while the overall operating profit, including other income, increased from 0.46 Cr to 1.89 Cr in the same period. Profit before tax peaked at 1.42 Cr in Mar'25, although it slightly declined from 1.57 Cr in Mar'24. Profit after tax also saw growth, reaching 1.03 Cr in Mar'25 compared to 0.36 Cr in Mar'21. Th...

When is the next results date for EP Biocomposites?

2025-10-31 23:17:16

The next results date for EP Biocomposites is scheduled for November 3, 2025....

Why is EP Biocomposites falling/rising?

2025-10-28 23:03:20

As of 27-Oct, EP Biocomposites Ltd is experiencing a decline in its stock price, currently at 123.00, which represents a decrease of 13.0 points or 9.56%. The stock has underperformed its sector today by 10.17%, opening with a significant loss of 13.16% and touching an intraday low of Rs 118.1. Over the past week, the stock has decreased by 2.38%, and year-to-date, it has fallen by 28.07%. Additionally, there has been erratic trading, with the stock not trading on 2 out of the last 20 days, and a notable drop in investor participation, as evidenced by a 37.5% decrease in delivery volume compared to the 5-day average. Unfortunately, there is no information available regarding positive or negative factors impacting the stock. Broader market context shows that while EP Biocomposites has struggled, the Sensex has gained 0.49% over the past week and 8.50% year-to-date. This stark contrast highlights the stock's...

Why is EP Biocomposites falling/rising?

2025-10-24 23:57:38

As of 24-Oct, EP Biocomposites Ltd's stock price is rising, currently at 136.00, reflecting an increase of 11.0 points or 8.8%. The stock opened with a significant gain of 8.8% today and has maintained this price level throughout the trading session. It has outperformed its sector by 9.91%, and there has been a notable increase in investor participation, with delivery volume rising by 11.11% compared to the 5-day average. Despite a year-to-date decline of 20.47% and a 1-year drop of 22.73%, the recent performance indicates a positive shift, particularly in the short term. In the broader market context, EP Biocomposites' 1-week return of 7.94% significantly outpaces the Sensex's modest gain of 0.31%, indicating a strong short-term performance relative to the benchmark. However, over the longer term, the stock has underperformed, with a 3-year decline of 53.10% compared to the Sensex's rise of 40.75%. This c...

Is EP Biocomposites overvalued or undervalued?

2025-10-10 08:06:13

As of 9 October 2025, the valuation grade for EP Biocomposites has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE Ratio of 20.73, an EV to EBITDA of 12.76, and a Price to Book Value of 2.02, which suggest that the stock is trading at a premium compared to its earnings and book value. In comparison to its peers, EP Biocomposites has a lower PE ratio than Altius Telecom, which stands at 54.74, but is higher than Embassy Off.REIT at 25.21. The PEG ratio for EP Biocomposites is notably 0.00, indicating no growth expectations factored into its valuation, which is concerning. Additionally, the company's stock has underperformed relative to the Sensex, with a year-to-date return of -25.73% compared to the Sensex's 5.16%, reinforcing the notion that the stock is overvalued in the current market e...

Why is EP Biocomposites falling/rising?

2025-10-09 00:11:06

As of 08-Oct, EP Biocomposites Ltd is currently priced at 120.00, with no change in price (0.00%). The stock has shown a significant decline over various periods, with a 6.21% drop in the past week and a 29.82% decrease year-to-date. Today's trading performance is inline with the sector, but the stock has exhibited erratic trading patterns, not trading on 3 out of the last 20 days. Additionally, it is trading below all key moving averages, indicating a bearish trend. However, there has been a notable increase in investor participation, with delivery volume rising by 650% against the 5-day average, suggesting some interest despite the overall downward trajectory. Broader Market Context: In comparison to the benchmark, the Sensex has performed positively, gaining 0.98% over the past week and 4.65% year-to-date, while EP Biocomposites has faced substantial losses. This stark contrast highlights the stock's un...

View All News